Clinical significance of miR-3178 in non-small cell lung cancer patients.

Background: Non-small cell lung cancer (NSCLC) is a malignant tumour with high morbidity and mortality, with a low survival rate and poor prognosis. This study aims to explore the diagnostic and prognostic value of miR-3178 in NSCLC. Methods: The study included 118 NSCLC patients and 97 healthy subjects. RT-qPCR measured miR-3178 and MIB2 in serum or cell lines. c 2 tests linked miR-3178 to clinico-pathological features. ROC, Kaplan-Meier, and Cox analyses evaluated the diagnostic and prognostic significance of miR-3178 and MIB2. Results: Compared to the control group, the expression level of miR-3178 was significantly reduced, while MIB2 expression was notably elevated in NSCLC patients. The expression of miR-3178 is significantly correlated with the TNM stage and LNM in NSCLC patients. NSCLC patients with higher miR-3178 expression levels exhibit significantly higher 5-year overall survival rates. Furthermore, TNM stage, miR-3178 expression, and MIB2 expression are independent risk factors that influence the prognosis of NSCLC. MIB2 serves as a target gene of miR-3178, and its expression levels display a significant negative correlation. When diagnosing NSCLC solely based on miR-3178, the AUC is 0.838, the diagnostic sensitivity and specificity were 83.1% and 72.2% , respectively; for MIB2 alone, the AUC is 0.818, the sensitivity and specificity were 76.3% and 72.2% ; however, when miR-3178 and MIB2 are combined for diagnosis, the AUC increases to 0.903, the sensitivity and specificity were 84.8% and 83.5%. Conclusions: The downregulation of miR-3178 and upregulation of MIB2 are associated with the progression and deterioration of NSCLC patients, indicating poor prognosis. miR-3178 targets MIB2, and their combined diagnosis can enhance the diagnostic value for NSCLC, potentially reducing the risk of adverse outcomes.